Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc
BBS-Bioactive Bone Substitutes Plc, Company Announcement, 23 October 2023 at 4.30 pm (EET)
Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone Substitutes Plc
BBS-Bioactive Bone Substitutes Plc’s Extraordinary General Meeting (EGM) was held at the company’s premises in Oulu on Monday 23 October 2023 starting at 2.00 pm (EET).
The Extraordinary General Meeting authorized the Board of Directors to decide in one or more instalments on share issues and on the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act as follows:
The maximum number of shares to be issued pursuant to the authorization shall not exceed 6,000,000 shares.
The Board of Directors decides on all terms and conditions for issuing shares, options and other special rights entitling to shares. Share issues and the issuance of option rights and other special rights entitling to shares may take place in deviation from the shareholders' pre-emptive subscription right (directed issue) if there is a weighty financial reason for the company to do so. The authorization applies to the transfer of both new shares and own shares held by the company.
In the company's share issue, shares may be transferred either in exchange for payment or free of charge. A directed share issue may be free of charge only if there is a particularly significant financial reason for the company and it is in the interests of all its shareholders.
The authorization is valid until 23 October 2027 and it revokes the authorization granted by the Annual General Meeting on 30 March 2023 as it enters into force.
The Company currently has a total of 14,618,847 shares, and holds no treasury shares.
The minutes of the EGM will be made available on the Company’s website www.bbs-artebone.fi.
In Oulu, 23 October 2023
BBS-Bioactive Bone Substitutes Plc
Board of Directors
For more information:
Pekka Jalovaara, Chair of the board
puh. +358 50 552 9275
Nordic Certified Adviser AB,
tel. +46 70 551 67 29, firstname.lastname@example.org
Nasdaq Helsinki Oy
BBS in brief
BBS-Bioactive Bone Substitutes Plc is a orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. We have a track record of over 20 years in this field. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our developed product, ARTEBONE®, is in the final stages of product development, and we are seeking the CE marking to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ 20 people.
BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.
More information: www.bbs-artebone.fiTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Registration of share capital increase in IDEX Biometrics 1 Dec 20231.12.2023 17:30:00 CET | Press release
Reference is made to the notice on 21 November 2023 regarding employees having exercised 389,608 incentive subscription rights at NOK 0.15 per share. The capital increase has been registered and the shares will be delivered soonest. Following the issue, the company's share capital is NOK 209,551,597.20 divided into 1,397,010,648 shares, each with a nominal value of NOK 0.15. For further information contact: Marianne Bøe, Investor Relations E-mail: email@example.com Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As
Innofactor Plc: Share Repurchase 1.12.20231.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 1.12.2023Innofactor Plc: Share Repurchase 1.12.2023In the Helsinki Stock ExchangeTrade date 1.12.2023Bourse trade BuyShare IFA1VAmount 4,600SharesAverage price/ share 1.1500EURTotal cost 5,290.00EURInnofactor Plc now holds a total of 561 829 sharesincluding the shares repurchased on 1.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment IFA1V ENG 134
Wolters Kluwer named as a Leader in Gartner® Magic Quadrant™ for Financial Close and Consolidation Solutions1.12.2023 17:29:28 CET | Press release
PRESS RELEASE Wolters Kluwer named as a Leader in Gartner® Magic Quadrant™ for Financial Close and Consolidation Solutions Wolters Kluwer CCH Tagetik platform facilitates the end-to-end financial closing process, from account reconciliation and AI-based transaction matching to financial and management reporting and disclosure. NEW YORK – Dec. 1, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Close and Consolidation Solutions, based on its completeness of vision and ability to execute. Last month, Wolters Kluwer was also recognized in the 2023 Gartner Market Guide for Financial Reconciliation Solutions. The CCH Tagetik Financial Close & Consolidation platform improves the speed and accuracy of all aspects of the financial close and consolidation process, ranging from account reconciliation and transaction matching to financial, ma
TGS Shareholders Approve the Merger Plan with PGS1.12.2023 17:09:37 CET | Press release
OSLO, Norway (1 December 2023) - Reference is made to the joint stock exchange announcement on 18 September 2023 by TGS ASA ("TGS" or the "Company," OSE: TGS) and PGS ASA ("PGS," OSE: PGS) regarding the combination of the two companies (the "Merger") to establish the premier energy data company, as well as subsequent announcements on 25 and 30 October 2023 regarding, respectively, the execution of the definitive merger agreement and notices for extraordinary general meetings for approval. An extraordinary general meeting in TGS was held today at 16:00 hours (Oslo time) as a virtual meeting. All proposals on the agenda were approved with requisite majorities, including the merger plan dated 25 October 2023 and the corresponding share capital increase in the Company. As separately announced by PGS earlier today, the merger has also been approved by the extraordinary general meeting in PGS. As a consequence, the decision to approve the merger will now be filed with the Norwegian Register
Festi hf.: Buyback program week 48 – end of buyback1.12.2023 16:58:38 CET | Press release
In week 48 2023, Festi purchased in total 19,260 own shares for total amount of 3,409,020 ISK as follows: WeekDateTimePurchased shareSahre pricePurchase price 48 29.nov 11:51:24 19.260 177 3.409.020 19.2603.409.020 The execution of the buyback program is in accordance with the Act on Public Limited Companies No 2/1995, Article 5 of the Regulation of the European parliament and of the Council No. 596/2014, on market abuse, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase Festi held 3,226,966 own shares or 1.06% of issued shares. Festi has now bought in total 3,246,226 own shares (1.07% of issued shares) for 599,999,945 ISK and has finished the buyback. This announcement of purchase of own shares is in accordance with the buyback program announced 21 July 2023 to Nasdaq OMX Iceland. The program envisages the buyback of a total of 3,500,000 own shares or 1.15% of the issued shares, with the cap of 600 million I